Medic Life Sciences employs advanced technologies to revolutionize cancer drug development through its proprietary CRISPR functional genomics platform. This platform integrates a unique tumor-immune co-culture system that allows for the systematic discovery of cancer biomarkers, synthetic lethality, and resistant mutations. By utilizing 3D tumor models that closely mimic patient tumors, the company can accurately assess the functional contributions of various cancer mutations, enabling the identification of both tumor-intrinsic and immuno-oncological drug targets. This approach not only enhances the understanding of drug response and resistance mechanisms but also facilitates the development of personalized cancer therapies.

The company's innovative methodology focuses on the systematic installation of CRISPR variants that replicate cancer mutations, which aids in uncovering key genetic features essential for drug development. By identifying molecular biomarkers, Medic Life Sciences aims to stratify patients for more effective treatment options, thereby improving clinical outcomes. Their research into synthetic lethality further allows for the design of targeted therapies that exploit specific genetic vulnerabilities in cancer cells, exemplified by the use of PARP inhibitors in BRCA-mutated cancers. Overall, Medic Life Sciences is committed to advancing cancer treatment through cutting-edge technologies that enhance the precision and efficacy of drug development.

United States

MEDIC Life Sciences is a biotechnology company that specializes in resurrecting cancer drugs from failed clinical trials using proprietary technology to produce 2 million different tumor samples for testing.

Medic Life Sciences

Company Details